Evidence map›Paper›PMID 42564054›Full record

ArticleFrontiers in cellular and infection microbiology2026

Clinical characteristics and outcomes of liver transplant recipients with carbapenem resistant klebsiella pneumonia infection.

Yan Dang, Ning Liu, Gengxia Yang, Ming Chen, Xiurong Ding, Fangfang Dai, Yanhua Yu, Jinli Lou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yan DangDepartment of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ning LiuDepartment of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Gengxia YangDepartment of General Surgery, Liver Transplantation Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ming ChenDepartment of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xiurong DingDepartment of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Fangfang DaiDepartment of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yanhua YuDepartment of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Jinli LouDepartment of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carbapenem resistant klebsiella pneumoniae infection increased the mortality rate of liver transplant recipients. This study aims to provide more evidence for the clinical diagnosis and treatment of carbapenem resistant klebsiella pneumonia infection in liver transplant recipients. Methods: This study included liver transplant recipients who developed CRKP infections during the perioperative period from January 2019 to December 2024 at Beijing You'an Hospital. Statistical analysis was performed on their clinical and outcomes characteristics. Results: Among the 48 liver transplant recipients with CRKP infections, the 30 days mortality rate and the 90 days mortality rate after infection was 25%(12/48) and 31.25%(15/48). The mortality rates of patients with abdominal cavity infections were significantly higher than those of other patients ( Conclusion: Clinicians should remain vigilant for abdominal infections, promptly control the infection source, and recognize early signs of septic shock to initiate timely treatment-key measures to reduce mortality for liver transplant recipients with CRKP infection. Additionally, effective antibiotic therapy within 48 hours after sampling may confer a survival benefit.

Indexed as

Anti-Bacterial AgentsCarbapenem-Resistant EnterobacteriaceaeCarbapenemsKlebsiella InfectionsKlebsiella pneumoniaeLiver TransplantationTransplant RecipientsAdultAgedAzabicyclo CompoundsCeftazidimeDrug CombinationsFemaleHumansMaleMicrobial Sensitivity TestsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCarbapenemsCeftazidimeDrug CombinationsThird Generation Cephalosporinscarbapenemsceftazidime-avibactamklebsiella pneumoniaeliver transplantationoutcomes

Identifiers

PMID42564054
PMCPMC13441731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.